Zentalis Extends Cash Runway Into First Half of 2028

The Tip Desk · November 9, 2026 · 3 min read

Cash, cash equivalents and marketable securities reached $228.9 million after an August equity raise, while the company still targets a first-half 2027 DENALI topline readout.

Zentalis Pharmaceuticals (ZNTL), a clinical oncology company developing the investigational WEE1 inhibitor azenosertib, reported cash, cash equivalents and marketable securities of $228.9 million as of September 30, 2026, up from $174.6 million at June 30, 2026, after an August follow-on offering of 26,450,000 shares that raised about $86.9 million in net proceeds.

The company said existing cash will fund operating expenses and capital expenditure into the first half of 2028, extending the runway it had described as into late 2027 after the June 30 close.

Chief Executive Officer Julie Eastland said the company plans to discuss DENALI data with the FDA in 2027 to assess an accelerated approval opportunity in platinum-resistant ovarian cancer, citing an evolving treatment landscape, while continuing the Phase 3 ASPENOVA trial at full speed. DENALI Part 2c enrollment, still open in the June 30 update, is scheduled to complete in November 2026; Parts 2a and 2b are complete. Zentalis still expects an integrated DENALI Part 2 topline readout in the first half of 2027.

At the October 2026 ESMO meeting, the company presented DENALI Part 1b overall survival in patients with platinum-resistant ovarian cancer. In Cyclin E1-positive patients (n=48), median overall survival was 15.9 months (95% CI, 8.7–21.2), versus 7.5 months (95% CI, 5.8–12.3) in Cyclin E1-negative patients (n=46). Updated overall response rate in response-evaluable Cyclin E1-positive patients was 37.2%, with a median duration of response of 5.5 months, including two patients with responses exceeding 15 and 20 months. Median relative dose intensity was 84.6%.

ASPENOVA, the randomized Phase 3 trial designed to support full approval of azenosertib in Cyclin E1-positive PROC, is enrolling, with site initiations and enrollment described as advancing across multiple geographies. The trial is expected to enroll about 420 patients and compare azenosertib 400 mg once daily on a 5-days-on, 2-days-off schedule with investigator’s choice of standard-of-care single-agent chemotherapy; the primary endpoint is progression-free survival.

MUIR Part 2 enrollment of azenosertib plus bevacizumab as maintenance in second-line platinum-sensitive ovarian cancer is ongoing. Zentalis said it is actively planning a combination clinical study in triple-negative breast cancer.

Research and development expenses for the three months ended September 30, 2026 were $22.3 million, down $0.7 million from $23.0 million a year earlier. The company attributed the decline primarily to a $6.2 million decrease in clinical trial expenses for studies that reached or are near completion, partially offset by a $3.8 million increase in ongoing trials open for enrollment, a $0.8 million increase in companion diagnostic development, and a $0.9 million increase in personnel-related expenses and allocated overhead.

General and administrative expenses were $8.8 million, down $2.0 million from $10.8 million a year earlier, primarily a $2.7 million decrease in personnel-related expenses partially offset by a $0.7 million increase in consulting and outside services. Total operating expenses were $31.2 million.

Net loss for the three months ended September 30, 2026 was $28.8 million, or $0.34 a share, versus $26.7 million, or $0.37 a share, a year earlier. Investment and other income, net, fell to $2.5 million from $7.0 million.

Azenosertib has not been approved by the FDA or any other regulatory authority. DENALI Part 2 is designed to support an accelerated approval pathway in the Cyclin E1-positive population, subject to the strength of the data, FDA feedback and the treatment landscape at the time of regulatory action.